Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages

Area of Science:

• Oncology
• Cancer Research
• Epidemiology

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is often viewed as a rapidly progressing disease.
• Mathematical models suggest a long preclinical development period for PDAC.
• Understanding PDAC progression through clinical stages is crucial for treatment strategies.

Purpose of the Study:

• To estimate the time it takes for pancreatic cancer to progress through different tumor, node, metastasis (TNM) stages.
• To compare the mean age of patients diagnosed with pancreatic cancers of varying sizes and stages.

Main Methods:

• Analysis of patient age, tumor size, stage, and demographic data for 13,131 patients with PDAC from the National Cancer Institute's SEER database.
• Utilized multiple linear regression models for age, adjusting for ethnicity, gender, tumor location, and neoplastic grades.

Main Results:

• Earlier age at diagnosis was associated with African-American ethnicity and male gender.
• Patients with Stage I PDAC were diagnosed at a younger mean age (64.8 years) compared to Stage IV (p=0.001).
• Smaller tumors (T1) were associated with younger diagnosis ages than larger tumors (T3/T4) among patients without distant metastases (p=0.03).

Conclusions:

• Findings support the hypothesis that PDAC progression is rapid once clinically detectable.
• The clinical progression from early-stage to advanced-stage pancreatic cancer appears to occur quickly.